A phase 2 trial of radiation therapy with concurrent paclitaxel chemotherapy after surgery in patients with high-risk endometrial cancer

A Korean Gynecologic Oncologic Group study

Hanbyoul Cho, Byung Ho Nam, Seok Mo Kim, Chi Heum Cho, Byoung Gie Kim, Hee Sug Ryu, Soon Beom Kang, Jae-Hoon Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose A phase 2 study was completed by the Korean Gynecologic Oncologic Group to evaluate the efficacy and toxicity of concurrent chemoradiation with weekly paclitaxel in patients with high-risk endometrial cancer. Methods and Materials Pathologic requirements included endometrial endometrioid adenocarcinoma stages III and IV. Radiation therapy consisted of a total dose of 4500 to 5040 cGy in 5 fractions per week for 6 weeks. Paclitaxel 60 mg/m 2 was administered once weekly for 5 weeks during radiation therapy. Results Fifty-seven patients were enrolled between January 2006 and March 2008. The median follow-up time was 60.0 months (95% confidence interval [CI], 51.0-58.2). All grade 3/4 toxicities were hematologic and usually self-limited. There was no life-threatening toxicity. The cumulative incidence of intrapelvic recurrence sites was 1.9% (1/52), and the cumulative incidence of extrapelvic recurrence sites was 34.6% (18/52). The estimated 5-year disease-free and overall survival rates were 63.5% (95% CI, 50.4-76.5) and 82.7% (95% CI, 72.4-92.9), respectively. Conclusions Concurrent chemoradiation with weekly paclitaxel is well tolerated and seems to be effective for high-risk endometrioid endometrial cancers. This approach appears reasonable to be tested for efficacy in a prospective, randomized controlled study.

Original languageEnglish
Pages (from-to)140-146
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume90
Issue number1
DOIs
Publication statusPublished - 2014 Sep 1

Fingerprint

chemotherapy
Endometrial Neoplasms
Paclitaxel
surgery
toxicity
confidence
radiation therapy
Radiotherapy
cancer
Confidence Intervals
intervals
Drug Therapy
incidence
Endometrioid Carcinoma
Recurrence
Incidence
Disease-Free Survival
grade
Survival Rate
dosage

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{84eddb83fe8e4b65bd10a8f8e61b989f,
title = "A phase 2 trial of radiation therapy with concurrent paclitaxel chemotherapy after surgery in patients with high-risk endometrial cancer: A Korean Gynecologic Oncologic Group study",
abstract = "Purpose A phase 2 study was completed by the Korean Gynecologic Oncologic Group to evaluate the efficacy and toxicity of concurrent chemoradiation with weekly paclitaxel in patients with high-risk endometrial cancer. Methods and Materials Pathologic requirements included endometrial endometrioid adenocarcinoma stages III and IV. Radiation therapy consisted of a total dose of 4500 to 5040 cGy in 5 fractions per week for 6 weeks. Paclitaxel 60 mg/m 2 was administered once weekly for 5 weeks during radiation therapy. Results Fifty-seven patients were enrolled between January 2006 and March 2008. The median follow-up time was 60.0 months (95{\%} confidence interval [CI], 51.0-58.2). All grade 3/4 toxicities were hematologic and usually self-limited. There was no life-threatening toxicity. The cumulative incidence of intrapelvic recurrence sites was 1.9{\%} (1/52), and the cumulative incidence of extrapelvic recurrence sites was 34.6{\%} (18/52). The estimated 5-year disease-free and overall survival rates were 63.5{\%} (95{\%} CI, 50.4-76.5) and 82.7{\%} (95{\%} CI, 72.4-92.9), respectively. Conclusions Concurrent chemoradiation with weekly paclitaxel is well tolerated and seems to be effective for high-risk endometrioid endometrial cancers. This approach appears reasonable to be tested for efficacy in a prospective, randomized controlled study.",
author = "Hanbyoul Cho and Nam, {Byung Ho} and Kim, {Seok Mo} and Cho, {Chi Heum} and Kim, {Byoung Gie} and Ryu, {Hee Sug} and Kang, {Soon Beom} and Jae-Hoon Kim",
year = "2014",
month = "9",
day = "1",
doi = "10.1016/j.ijrobp.2014.05.024",
language = "English",
volume = "90",
pages = "140--146",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

A phase 2 trial of radiation therapy with concurrent paclitaxel chemotherapy after surgery in patients with high-risk endometrial cancer : A Korean Gynecologic Oncologic Group study. / Cho, Hanbyoul; Nam, Byung Ho; Kim, Seok Mo; Cho, Chi Heum; Kim, Byoung Gie; Ryu, Hee Sug; Kang, Soon Beom; Kim, Jae-Hoon.

In: International Journal of Radiation Oncology Biology Physics, Vol. 90, No. 1, 01.09.2014, p. 140-146.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase 2 trial of radiation therapy with concurrent paclitaxel chemotherapy after surgery in patients with high-risk endometrial cancer

T2 - A Korean Gynecologic Oncologic Group study

AU - Cho, Hanbyoul

AU - Nam, Byung Ho

AU - Kim, Seok Mo

AU - Cho, Chi Heum

AU - Kim, Byoung Gie

AU - Ryu, Hee Sug

AU - Kang, Soon Beom

AU - Kim, Jae-Hoon

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Purpose A phase 2 study was completed by the Korean Gynecologic Oncologic Group to evaluate the efficacy and toxicity of concurrent chemoradiation with weekly paclitaxel in patients with high-risk endometrial cancer. Methods and Materials Pathologic requirements included endometrial endometrioid adenocarcinoma stages III and IV. Radiation therapy consisted of a total dose of 4500 to 5040 cGy in 5 fractions per week for 6 weeks. Paclitaxel 60 mg/m 2 was administered once weekly for 5 weeks during radiation therapy. Results Fifty-seven patients were enrolled between January 2006 and March 2008. The median follow-up time was 60.0 months (95% confidence interval [CI], 51.0-58.2). All grade 3/4 toxicities were hematologic and usually self-limited. There was no life-threatening toxicity. The cumulative incidence of intrapelvic recurrence sites was 1.9% (1/52), and the cumulative incidence of extrapelvic recurrence sites was 34.6% (18/52). The estimated 5-year disease-free and overall survival rates were 63.5% (95% CI, 50.4-76.5) and 82.7% (95% CI, 72.4-92.9), respectively. Conclusions Concurrent chemoradiation with weekly paclitaxel is well tolerated and seems to be effective for high-risk endometrioid endometrial cancers. This approach appears reasonable to be tested for efficacy in a prospective, randomized controlled study.

AB - Purpose A phase 2 study was completed by the Korean Gynecologic Oncologic Group to evaluate the efficacy and toxicity of concurrent chemoradiation with weekly paclitaxel in patients with high-risk endometrial cancer. Methods and Materials Pathologic requirements included endometrial endometrioid adenocarcinoma stages III and IV. Radiation therapy consisted of a total dose of 4500 to 5040 cGy in 5 fractions per week for 6 weeks. Paclitaxel 60 mg/m 2 was administered once weekly for 5 weeks during radiation therapy. Results Fifty-seven patients were enrolled between January 2006 and March 2008. The median follow-up time was 60.0 months (95% confidence interval [CI], 51.0-58.2). All grade 3/4 toxicities were hematologic and usually self-limited. There was no life-threatening toxicity. The cumulative incidence of intrapelvic recurrence sites was 1.9% (1/52), and the cumulative incidence of extrapelvic recurrence sites was 34.6% (18/52). The estimated 5-year disease-free and overall survival rates were 63.5% (95% CI, 50.4-76.5) and 82.7% (95% CI, 72.4-92.9), respectively. Conclusions Concurrent chemoradiation with weekly paclitaxel is well tolerated and seems to be effective for high-risk endometrioid endometrial cancers. This approach appears reasonable to be tested for efficacy in a prospective, randomized controlled study.

UR - http://www.scopus.com/inward/record.url?scp=84905920281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905920281&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2014.05.024

DO - 10.1016/j.ijrobp.2014.05.024

M3 - Article

VL - 90

SP - 140

EP - 146

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -